Gene-Environment Interactions in Progressive Supranuclear Palsy

Several genetic and environmental factors have been reported in progressive supranuclear palsy (PSP), although none were identified as a definitive cause. We aimed to explore potential gene-environment interactions in PSP. Two hundred and ninety two PSP cases and 292 controls matched for age, sex, and race from the ENGENE-PSP were analyzed to determine the association between PSP and minor alleles of 5 single nucleotide polymorphisms (SNPs) in 4 genes (MAPT, MOBP, EIF2AK3, and STX6), which were previously associated with PSP risk. Interactions between these SNPs and environmental factors, including previously reported occupational and agricultural risk factors for PSP, were assessed for PSP odds and age of symptom onset. Minor alleles of MAPTrs242557 and EIF2AK3rs7571971 were individually associated with increased odds; MAPTrs8070723 minor alleles were associated with lower PSP odds. There were several gene-environment interactions for PSP odds and age of symptom onset, however, they did not remain significant after FDR-correction. Larger scale studies are required to determine potential interactions.

[1]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[2]  D. Galasko,et al.  4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration , 2019, Acta Neuropathologica.

[3]  Ashley R. Jones,et al.  Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases , 2018, Molecular Neurodegeneration.

[4]  G. Schellenberg,et al.  Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci , 2018, Molecular Neurodegeneration.

[5]  I. Litvan,et al.  Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans , 2018, Front. Neurol..

[6]  J. Hardy,et al.  Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype , 2018, bioRxiv.

[7]  Nicolas Nicastro,et al.  Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. , 2018, Parkinsonism & related disorders.

[8]  A. Lang,et al.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches , 2017, The Lancet Neurology.

[9]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[10]  K. Nakashima,et al.  Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade , 2016, Brain and behavior.

[11]  J. Rowe,et al.  Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes , 2016, Neurology.

[12]  S. Rai,et al.  Environmental and occupational risk factors for progressive supranuclear palsy: Case‐control study , 2016, Movement disorders : official journal of the Movement Disorder Society.

[13]  L. Buée,et al.  A geographical cluster of progressive supranuclear palsy in northern France , 2015, Neurology.

[14]  Murray Grossman,et al.  Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy , 2015, Nature Communications.

[15]  Lauren E. W. Olsho,et al.  A Method to screen U.S. environmental biomonitoring data for race/ethnicity and income-related disparity , 2013, Environmental Health.

[16]  M. Kitamura,et al.  The unfolded protein response triggered by environmental factors , 2013, Seminars in Immunopathology.

[17]  Andrew J. Lees,et al.  Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy , 2011, Nature Genetics.

[18]  L. Buée,et al.  Nuclear Tau, a Key Player in Neuronal DNA Protection* , 2010, The Journal of Biological Chemistry.

[19]  W. Kamphorst,et al.  Survival in progressive supranuclear palsy and frontotemporal dementia , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  M. Vidailhet,et al.  Risk factors for progressive supranuclear palsy: a case-control study in France , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  M. Ruberg,et al.  The PSP‐associated MAPT H1 subhaplotype in Guadeloupean atypical Parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[22]  L. Golbe,et al.  A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.

[23]  Romana Höftberger,et al.  Endoplasmic Reticulum Stress Features Are Prominent in Alzheimer Disease but Not in Prion Diseases In Vivo , 2006, Journal of neuropathology and experimental neurology.

[24]  K. Nakashima,et al.  Prevalence of progressive supranuclear palsy in Yonago, Japan , 2004, Movement disorders : official journal of the Movement Disorder Society.

[25]  D. Burn,et al.  The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. , 2001, Brain : a journal of neurology.

[26]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[27]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[28]  D. Schaid,et al.  Validation of a telephone questionnaire for Parkinson's disease. , 1998, Journal of clinical epidemiology.

[29]  P. Stewart,et al.  A novel approach to data collection in a case-control study of cancer and occupational exposures. , 1996, International journal of epidemiology.

[30]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[31]  R. Cody,et al.  Follow-up study of risk factors in progressive supranuclear palsy , 1996, Neurology.

[32]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[33]  Chia-Wen Lu,et al.  A cross sectional study , 2019 .

[34]  C. McCarty,et al.  Open Access Research Article Population Based Allele Frequencies of Disease Associated Polymorphisms in the Personalized Medicine Research Project , 2022 .